448 related articles for article (PubMed ID: 30550751)
41. Inhibition of Drp1 protects against senecionine-induced mitochondria-mediated apoptosis in primary hepatocytes and in mice.
Yang X; Wang H; Ni HM; Xiong A; Wang Z; Sesaki H; Ding WX; Yang L
Redox Biol; 2017 Aug; 12():264-273. PubMed ID: 28282614
[TBL] [Abstract][Full Text] [Related]
42. Transgenic mice expressing mutated full-length HD cDNA: a paradigm for locomotor changes and selective neuronal loss in Huntington's disease.
Reddy PH; Charles V; Williams M; Miller G; Whetsell WO; Tagle DA
Philos Trans R Soc Lond B Biol Sci; 1999 Jun; 354(1386):1035-45. PubMed ID: 10434303
[TBL] [Abstract][Full Text] [Related]
43. A conserved, noncanonical insert in FIS1 mediates TBC1D15 and DRP1 recruitment for mitochondrial fission.
Ihenacho UK; Toro R; Mansour RH; Hill RB
J Biol Chem; 2023 Nov; 299(11):105303. PubMed ID: 37777154
[TBL] [Abstract][Full Text] [Related]
44. Mutant huntingtin, abnormal mitochondrial dynamics, defective axonal transport of mitochondria, and selective synaptic degeneration in Huntington's disease.
Reddy PH; Shirendeb UP
Biochim Biophys Acta; 2012 Feb; 1822(2):101-10. PubMed ID: 22080977
[TBL] [Abstract][Full Text] [Related]
45. Amelioration of Huntington's disease phenotype in astrocytes derived from iPSC-derived neural progenitor cells of Huntington's disease monkeys.
Cho IK; Yang B; Forest C; Qian L; Chan AWS
PLoS One; 2019; 14(3):e0214156. PubMed ID: 30897183
[TBL] [Abstract][Full Text] [Related]
46. Dynamin-related protein 1: A critical protein in the pathogenesis of neural system dysfunctions and neurodegenerative diseases.
Qi Z; Huang Z; Xie F; Chen L
J Cell Physiol; 2019 Jul; 234(7):10032-10046. PubMed ID: 30515821
[TBL] [Abstract][Full Text] [Related]
47. Bcl-2/adenovirus E1B 19-kDa interacting protein (BNip3) has a key role in the mitochondrial dysfunction induced by mutant huntingtin.
Sassone F; Margulets V; Maraschi A; Rodighiero S; Passafaro M; Silani V; Ciammola A; Kirshenbaum LA; Sassone J
Hum Mol Genet; 2015 Nov; 24(22):6530-9. PubMed ID: 26358776
[TBL] [Abstract][Full Text] [Related]
48. Involvement of CRMP2 in Regulation of Mitochondrial Morphology and Motility in Huntington's Disease.
Brustovetsky T; Khanna R; Brustovetsky N
Cells; 2021 Nov; 10(11):. PubMed ID: 34831395
[TBL] [Abstract][Full Text] [Related]
49. Dynamin-related protein 1 and mitochondrial fragmentation in neurodegenerative diseases.
Reddy PH; Reddy TP; Manczak M; Calkins MJ; Shirendeb U; Mao P
Brain Res Rev; 2011 Jun; 67(1-2):103-18. PubMed ID: 21145355
[TBL] [Abstract][Full Text] [Related]
50. Insulin and IGF-1 improve mitochondrial function in a PI-3K/Akt-dependent manner and reduce mitochondrial generation of reactive oxygen species in Huntington's disease knock-in striatal cells.
Ribeiro M; Rosenstock TR; Oliveira AM; Oliveira CR; Rego AC
Free Radic Biol Med; 2014 Sep; 74():129-44. PubMed ID: 24992836
[TBL] [Abstract][Full Text] [Related]
51. Small-molecule suppression of calpastatin degradation reduces neuropathology in models of Huntington's disease.
Hu D; Sun X; Magpusao A; Fedorov Y; Thompson M; Wang B; Lundberg K; Adams DJ; Qi X
Nat Commun; 2021 Sep; 12(1):5305. PubMed ID: 34489447
[TBL] [Abstract][Full Text] [Related]
52. PINK1-induced mitophagy promotes neuroprotection in Huntington's disease.
Khalil B; El Fissi N; Aouane A; Cabirol-Pol MJ; Rival T; Liévens JC
Cell Death Dis; 2015 Jan; 6(1):e1617. PubMed ID: 25611391
[TBL] [Abstract][Full Text] [Related]
53. Nature and cause of mitochondrial dysfunction in Huntington's disease: focusing on huntingtin and the striatum.
Oliveira JM
J Neurochem; 2010 Jul; 114(1):1-12. PubMed ID: 20403078
[TBL] [Abstract][Full Text] [Related]
54. Mutant huntingtin causes context-dependent neurodegeneration in mice with Huntington's disease.
Yu ZX; Li SH; Evans J; Pillarisetti A; Li H; Li XJ
J Neurosci; 2003 Mar; 23(6):2193-202. PubMed ID: 12657678
[TBL] [Abstract][Full Text] [Related]
55. Fine-tuning of Drp1/Fis1 availability by AKAP121/Siah2 regulates mitochondrial adaptation to hypoxia.
Kim H; Scimia MC; Wilkinson D; Trelles RD; Wood MR; Bowtell D; Dillin A; Mercola M; Ronai ZA
Mol Cell; 2011 Nov; 44(4):532-44. PubMed ID: 22099302
[TBL] [Abstract][Full Text] [Related]
56. Identification of Novel Therapeutic Targets for Polyglutamine Diseases That Target Mitochondrial Fragmentation.
Traa A; Machiela E; Rudich PD; Soo SK; Senchuk MM; Van Raamsdonk JM
Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34948242
[TBL] [Abstract][Full Text] [Related]
57. Cardiac dysfunction in the R6/2 mouse model of Huntington's disease.
Mihm MJ; Amann DM; Schanbacher BL; Altschuld RA; Bauer JA; Hoyt KR
Neurobiol Dis; 2007 Feb; 25(2):297-308. PubMed ID: 17126554
[TBL] [Abstract][Full Text] [Related]
58. Juvenile Huntington's Disease Skin Fibroblasts Respond with Elevated Parkin Level and Increased Proteasome Activity as a Potential Mechanism to Counterbalance the Pathological Consequences of Mutant Huntingtin Protein.
Aladdin A; Király R; Boto P; Regdon Z; Tar K
Int J Mol Sci; 2019 Oct; 20(21):. PubMed ID: 31717806
[TBL] [Abstract][Full Text] [Related]
59. Mitochondria in Huntington's disease.
Damiano M; Galvan L; Déglon N; Brouillet E
Biochim Biophys Acta; 2010 Jan; 1802(1):52-61. PubMed ID: 19682570
[TBL] [Abstract][Full Text] [Related]
60. Astrocytes generated from patient induced pluripotent stem cells recapitulate features of Huntington's disease patient cells.
Juopperi TA; Kim WR; Chiang CH; Yu H; Margolis RL; Ross CA; Ming GL; Song H
Mol Brain; 2012 May; 5():17. PubMed ID: 22613578
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
